Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Elie Rassy & Nicholas Pavlidis. (2020) The diagnostic challenges of patients with carcinoma of unknown primary. Expert Review of Anticancer Therapy 20:9, pages 775-783.
Read now
Read now
Articles from other publishers (14)
Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, Tilmann Bochtler & Alwin Krämer. (2023) Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nature Communications 14:1.
Crossref
Crossref
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong, Dipti Jain, Dilichukwu O Chudy Onwugaje, Abdulrahman Abonofal, Anneleis F Willett, Michael Overman, Brandon Smaglo, Ryan W Huey, Funda Meric-Bernstam, Gauri R Varadhachary & Aung Naing. (2022) Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for ImmunoTherapy of Cancer 10:5, pages e004822.
Crossref
Crossref
Ferrán Losa, Isaura Fernández, Olatz Etxaniz, Alejandra Giménez, Paula Gomila, Lara Iglesias, Federico Longo, Esteban Nogales, Antonio Sánchez & Gemma Soler. (2022) SEOM—GECOD clinical guideline for unknown primary cancer (2021). Clinical and Translational Oncology 24:4, pages 681-692.
Crossref
Crossref
Gerdt Hübner, Alwin Krämer & Stefan Janssen. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
30
.
Elie Rassy & Nicholas Pavlidis. (2020) Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nature Reviews Clinical Oncology 17:9, pages 541-554.
Crossref
Crossref
Maria Pouyiourou, Laura Claßen, Göran R. Boeckel, Tilmann Bochtler & Alwin Krämer. (2020) Das CUP-Syndrom - Stand 2020. InFo Hämatologie + Onkologie 23:4, pages 36-47.
Crossref
Crossref
Elie Rassy, Pauline Parent, Felix Lefort, Stergios Boussios, Giulia Baciarello & Nicholas Pavlidis. (2020) New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. Critical Reviews in Oncology/Hematology 147, pages 102882.
Crossref
Crossref
C. Schroten-Loef, R.H.A. Verhoeven, I.H.J.T. de Hingh, A.J. van de Wouw, H.W.M. van Laarhoven & V.E.P.P. Lemmens. (2018) Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012. European Journal of Cancer 101, pages 77-86.
Crossref
Crossref
Gerdt Hübner. (2017) Tumorerkrankung mit unbekanntem Primarius. Im Focus Onkologie 20:4, pages 46-53.
Crossref
Crossref
Dong-Yeop Shin, Yoon Hee Choi, Hyo-Rak Lee, Im Il Na, Young Jin Yuh, Bong-Seog Kim, Ik Joo Chung, Woo-Kyun Bae, Hyun-Jeong Shim, Eun-Kee Song, Sung Hyun Yang & Hye Jin Kang. (2015) A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. Cancer Chemotherapy and Pharmacology 77:1, pages 163-168.
Crossref
Crossref
Gerdt Hübner. 2016. Cancer of Unknown Primary. Cancer of Unknown Primary
113
123
.
M. Stahl & B. Brücher-Encke. (2012) CUP – Internistische Therapie bei ungünstigem RisikoprofilCUP – Systemic treatment in patients with unfavourable prognostic factors. Der Onkologe 19:1, pages 29-35.
Crossref
Crossref
Giulia Maria Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco & Paola Cassoni. (2012) Cancers of unknown primary origin: current perspectives and future therapeutic strategies. Journal of Translational Medicine 10:1.
Crossref
Crossref
Eric Yaovi Amela, Géraldine Lauridant-Philippin, Sophie Cousin, Thomas Ryckewaert, Antoine Adenis & Nicolas Penel. (2012) Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/Hematology 84:2, pages 213-223.
Crossref
Crossref